The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients.

Guillemette Emma BenoistInge M van OortDavid M BurgerNiven MehraNielka P van Erp

Published in: Cancer chemotherapy and pharmacology (2020)

We observed that age and BMI did not influence systemic exposure in patients treated with enzalutamide. No relation of exposure with efficacy or fatigue was observed. Further research using enzalutamide at a lower dose is needed to understand the relation of enzalutamide exposure and fatigue.

Keyphrases

prostate cancer
squamous cell carcinoma
small cell lung cancer
body mass index
sleep quality
physical activity
benign prostatic hyperplasia
smoking cessation